IL-6 as a marker for NMOSD disease activity

Barros, 2016, Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase, Clin. Exp. Immunol., 10.1111/cei.12733 Blanc, 2012, White matter atrophy and cognitive dysfunctions in neuromyelitis optica, PLoS One, 7, 10.1371/journal.pone.0033878 Carnero Contentti, 2021, Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies, J. Neuroinflammation, 18, 1, 10.1186/s12974-021-02249-1 Chihara, 2011, Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica, Proc. Natl. Acad. Sci. U. S. A., 10.1073/pnas.1017385108 Fujihara, 2020, Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology, Neurol. Neuroimmunol. neuroinflammation, 7, 1, 10.1212/NXI.0000000000000841 Hegde, 2016, International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Yearb. Ophthalmol. Heo, 2020, Satralizumab: First Approval, Drugs. Hostenbach, 2014, Astrocyte loss and astrogliosis in neuroinflammatory disorders, Neurosci. Lett., 565, 39, 10.1016/j.neulet.2013.10.012 Hyun, 2017, Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis, Eur. J. Neurol., 24, 437, 10.1111/ene.13224 Kishimoto, 1989, The biology of interleukin-6, Blood., 10.1182/blood.V74.1.1.1 Kong, 2017, Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder, J. Neuroinflammation, 14, 191, 10.1186/s12974-017-0961-z Levy, 2020, Interleukin-6 receptor blockade for the treatment of NMOSD, Lancet Neurol., 10.1016/S1474-4422(20)30081-8 Li, 2006, STATEMENT standardized MR imaging protocol for multiple sclerosis : consortium of MS centers consensus, Am. J. Neuroradiol., 27, 455 Liang, 2020, Impact of blood-brain barrier disruption on newly diagnosed neuromyelitis optica spectrum disorder symptoms and prognosis, Ann. Cardiothorac. Surg., 9, 324 Liu, 2015, Structural MRI substrates of cognitive impairment in neuromyelitis optica, Neurology, 85, 1491, 10.1212/WNL.0000000000002067 Manjón, 2016, volBrain: an online MRI brain Volumetry system, Front. Neuroinform., 10, 10.3389/fninf.2016.00030 Matsushita, 2013, Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis, PLoS One, 8, 2, 10.1371/journal.pone.0061835 Misu, 2007, Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis, Brain., 10.1093/brain/awm047 Rattazzi, 2003, C-reactive protein and interleukin-6 in vascular disease, J. Hypertens., 21, 1787, 10.1097/00004872-200310000-00002 Rechtman, 2022, 13, 1 Ringelstein, 2015, Long-term therapy with interleukin 6 receptor blockade in highly active Neuromyelitis Optica Spectrum disorder, JAMA Neurol., 72, 756, 10.1001/jamaneurol.2015.0533 Rochfort, 2014, Downregulation of blood-brain barrier phenotype by proinflammatory cytokines involves NADPH oxidase-dependent ROS generation: consequences for interendothelial adherens and tight junctions, PLoS One, 9, 10.1371/journal.pone.0101815 Rosso, 2020, Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options, Expert. Rev. Neurother., 20, 509, 10.1080/14737175.2020.1757434 Shimizu, 2017, Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica, Sci. Transl. Med., 9, 10.1126/scitranslmed.aai9111 Takeshita, 2017, Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro, Neurol. Neuroimmunol. Neuroinflammation, 4, 10.1212/NXI.0000000000000311 Takeshita, 2021, New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD, Neurol. Neuroimmunol. Neuroinflammation, 8, 1, 10.1212/NXI.0000000000001076 Tanaka, 2014, IL-6 in inflammation, immunity, and disease, Cold Spring Harb. Perspect. Biol., 6, a016295, 10.1101/cshperspect.a016295 Tillema, 2013, Neuroradiological evaluation of demyelinating disease, Ther. Adv. Neurol. Disord., 6, 249, 10.1177/1756285613478870 Uzawa, 2009, Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis, J. Neurol., 256, 2082, 10.1007/s00415-009-5274-4 Uzawa, 2010, Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6, Mult. Scler. J., 16, 1443, 10.1177/1352458510379247 Uzawa, 2010, Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6, Mult. Scler., 10.1177/1352458510379247 Uzawa, 2012, CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse, J. Neurol. Neurosurg. Psychiatry, 10.1136/jnnp.2011.241760 Wang, 2012, Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica, Neuroimmunomodulation., 10.1159/000339302 Wingerchuk, 2014 Wingerchuk, 2007, The spectrum of neuromyelitis optica, Lancet Neurol., 10.1016/S1474-4422(07)70216-8 Wu, 2019, Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models, Mult. Scler. Relat. Disord., 10.1016/j.msard.2018.12.002 Yandamuri, 2020, High-throughput investigation of molecular and cellular biomarkers in NMOSD, Neurol. Neuroimmunol. Neuroinflammation., 10.1212/NXI.0000000000000852